

# *Table of contents*

	<b>Page</b>
<b>Introduction.....</b>	<b>1</b>
<b>Aim of the work.....</b>	<b>3</b>
<b>Review of literature.....</b>	
➤ <b>Chapter 1:- AF.....</b>	<b>4</b>
▪ <b>Definition.</b>	<b>4</b>
▪ <b>Pathophysiology.</b>	<b>8</b>
▪ <b>Causes and clinical manifestations.</b>	<b>18</b>
▪ <b>Investigations.</b>	<b>22</b>
▪ <b>Therapy of AF.</b>	<b>24</b>
▪ <b>Non pharmacological therapy of AF.</b>	<b>34</b>
➤ <b>Chapter 2:-Antithrombotic therapy.....</b>	<b>40</b>
▪ <b>Recommendations of ACC, AHA&amp;ESC guidelines for management of antithrombotic therapy in AF.</b>	<b>40</b>
▪ <b>Risk stratifications.</b>	<b>44</b>
▪ <b>Therapeutic implications.</b>	<b>50</b>
▪ <b>Antithrombotic strategy for prevention of ischemic stroke&amp; systemic embolism.</b>	<b>55</b>
▪ <b>Emerging &amp; investigational antithrombotic agents.</b>	<b>67</b>
▪ <b>Interruption of anticoagulation for diagnostic &amp;therapeutic procedure.</b>	<b>71</b>
▪ <b>Anticoagulation for cardioversion in AF.</b>	<b>75</b>
<b>Patients and methods .....</b>	<b>80</b>
<b>Results.....</b>	<b>86</b>
<b>Case presentation .....</b>	<b>112</b>
<b>Discussion.....</b>	<b>118</b>
<b>Conclusion and Recommendations .....</b>	<b>128</b>
<b>Study Limitations.....</b>	<b>130</b>
<b>Summary.....</b>	<b>131</b>
<b>References.....</b>	<b>134</b>
<b>Master Sheet.....</b>	